NCT04696705 is a EARLY_PHASE1 clinical trial of Ex-vivo expanded allogeneic γδT cells in Non-Hodgkin's Lymphoma (NHL), sponsored by Institute of Hematology & Blood Diseases Hospital, China.

Who is sponsoring NCT04696705?

NCT04696705 is sponsored by Institute of Hematology & Blood Diseases Hospital, China.

What drugs are being tested in NCT04696705?

Interventions in NCT04696705: Ex-vivo expanded allogeneic γδT cells.

What condition does NCT04696705 study?

NCT04696705 studies Non-Hodgkin's Lymphoma (NHL), Peripheral T Cell Lymphoma (PTCL).

Is NCT04696705 still recruiting?

NCT04696705 is currently status unknown. Last updated 6 January 2021.

Last reviewed 2021-01-06 · How we verify

NCT04696705

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients

Status unknown EARLY_PHASE1 Last updated 6 January 2021

What this trial tests

EARLY_PHASE1 trial testing Ex-vivo expanded allogeneic γδT cells in Non-Hodgkin's Lymphoma (NHL) in 10 participants. Status unknown.

Timeline

31 December 2020

Primary endpoint
25 December 2021

25 December 2023

Quick facts

Lead sponsor	Institute of Hematology & Blood Diseases Hospital, China
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	31 December 2020
Primary completion	25 December 2021
Estimated completion	25 December 2023
Sites	1 location across China

Drugs / interventions tested

Ex-vivo expanded allogeneic γδT cells

Conditions studied

Non-Hodgkin's Lymphoma (NHL) — all drugs for Non-Hodgkin's Lymphoma (NHL) →
Peripheral T Cell Lymphoma (PTCL) — all drugs for Peripheral T Cell Lymphoma (PTCL) →

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Who can join

18 and older, any sex, with Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphoma (PTCL). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the safety, tolerability and efficacy of ex-vivo expanded allogeneic γδT cells obtained from a blood-related donor of patients with relapsed or refractory B cell non-Hodgkin's lymphoma (B-NHL) or peripheral T cell lymphoma (PTCL) expect for γδT lymphoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future.
Saura-Esteller J, de Jong M, King LA, Ensing E, et al · · 2022 · cited 144× · PMID 35784326 · DOI 10.3389/fimmu.2022.915837
Cancer immunotherapy by γδ T cells.
Hayday A, Dechanet-Merville J, Rossjohn J, Silva-Santos B. · · 2024 · cited 48× · PMID 39361750 · DOI 10.1126/science.abq7248
T Cell Based Immunotherapy for Cancer: Approaches and Strategies.
Want MY, Bashir Z, Najar RA. · · 2023 · cited 44× · PMID 37112747 · DOI 10.3390/vaccines11040835
A close look at current γδ T-cell immunotherapy.
Ma L, Feng Y, Zhou Z. · · 2023 · cited 35× · PMID 37063836 · DOI 10.3389/fimmu.2023.1140623
Allogeneic gamma delta T cells as adoptive cellular therapy for hematologic malignancies.
Jhita N, Raikar SS. · · 2022 · cited 34× · PMID 35783107 · DOI 10.37349/ei.2022.00054
Gamma/delta T cells as cellular vehicles for anti-tumor immunity.
Wang CQ, Lim PY, Tan AH. · · 2023 · cited 19× · PMID 38274800 · DOI 10.3389/fimmu.2023.1282758
Therapeutic avenues for γδ T cells in cancer.
Costa GP, Mensurado S, Silva-Santos B. · · 2023 · cited 17× · PMID 38007241 · DOI 10.1136/jitc-2023-007955
Potential of gamma/delta T cells for solid tumor immunotherapy.
Zhu D, Ren X, Xie W, Chen J, et al · · 2024 · cited 11× · PMID 39253082 · DOI 10.3389/fimmu.2024.1466266

Verify or expand the search:

Other trials of Ex-vivo expanded allogeneic γδT cells

Trials testing the same drug.

NCT04518774 — Allogeneic "Gammadelta T Cells (γδ T Cells)" Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical Trial · EARLY_PHASE1 · unknown

Other Institute of Hematology & Blood Diseases Hospital, China trials

Trials by the same sponsor.

NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04696705 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
Last refreshed: 6 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04696705.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing